Current β-adrenoblockers: scope of properties and substantiation of preferences
Perepech N.B., Mikhaylova I.E.
Epidemiological studies have shown that routine clinical practice uses β-adrenoblockers (BAB) less frequently than it is required. This is due to anxiety of physicians to induce side effects of BAB treatment, especially in the patients who might gain maximum clinical benefit from this therapy. Data provided in review show that the risk to benefit ratio depends to a considerable extent on choice of the drug. Furthermore the necessity is marked out for considering not only pathology and individual peculiarities of a patient but also pharmacokinetic characteristics of the drug.